The serum concentration of Escitalopram can be increased when it is combined with Aprepitant. The metabolism of Escitalopram can be decreased when combined with Rucaparib. The serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib. Mefloquine may increase the QTc-prolonging activities of Escitalopram. Azithromycin may increase the QTc-prolonging activities of Escitalopram. The metabolism of Escitalopram can be decreased when combined with Lumefantrine. The risk or severity of adverse effects can be increased when Sumatriptan is combined with Escitalopram. The risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram. The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Escitalopram. Escitalopram may increase the hypoglycemic activities of Liraglutide. The risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram. The risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram. The serum concentration of Escitalopram can be decreased when it is combined with Boceprevir. The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine. The serum concentration of Escitalopram can be decreased when it is combined with St. John's Wort. The risk or severity of adverse effects can be increased when Vortioxetine is combined with Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Prothipendyl. Iproniazid may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Cabergoline is combined with Escitalopram. Escitalopram may increase the antiplatelet activities of Parecoxib. Alfuzosin may increase the QTc-prolonging activities of Escitalopram. Escitalopram may increase the hypoglycemic activities of Insulin Glulisine. The risk or severity of adverse effects can be increased when Escitalopram is combined with Desvenlafaxine. The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram. Rilpivirine may increase the QTc-prolonging activities of Escitalopram. Dihydroetorphine may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Escitalopram. The risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram. Escitalopram may increase the hypoglycemic activities of Tolbutamide. The risk or severity of adverse effects can be increased when Opipramol is combined with Escitalopram. The risk or severity of adverse effects can be increased when Lidocaine is combined with Escitalopram. Telavancin may increase the QTc-prolonging activities of Escitalopram. The metabolism of Escitalopram can be decreased when combined with Terbinafine. Escitalopram may increase the hypoglycemic activities of Empagliflozin. The risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram. Escitalopram may increase the hypoglycemic activities of Tolazamide. Sertraline may increase the QTc-prolonging activities of Escitalopram. The metabolism of Escitalopram can be decreased when combined with Chloroquine. The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Escitalopram. The metabolism of Escitalopram can be decreased when combined with Ticlopidine. L-Tryptophan may increase the serotonergic activities of Escitalopram. The metabolism of Escitalopram can be decreased when combined with Saquinavir. The metabolism of Escitalopram can be decreased when combined with Lopinavir. The risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram. The metabolism of Escitalopram can be increased when combined with Rifapentine. The therapeutic efficacy of Liotrix can be decreased when used in combination with Escitalopram. Propafenone may increase the QTc-prolonging activities of Escitalopram. Escitalopram may increase the anticoagulant activities of Fluindione. The risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram. The risk or severity of adverse effects can be increased when Frovatriptan is combined with Escitalopram. The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Escitalopram. Escitalopram may increase the serotonergic activities of Dextromethorphan. Escitalopram may increase the hypoglycemic activities of Dulaglutide. Escitalopram may increase the antiplatelet activities of Rofecoxib. The risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram. The risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram. The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Escitalopram. Tolterodine may increase the QTc-prolonging activities of Escitalopram. Levomethadyl Acetate may increase the serotonergic activities of Escitalopram. Sorafenib may increase the QTc-prolonging activities of Escitalopram. The serum concentration of Escitalopram can be decreased when it is combined with Vemurafenib. Escitalopram may increase the hypoglycemic activities of Repaglinide. Indalpine may increase the serotonergic activities of Escitalopram. Goserelin may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Loxapine. Aripiprazole may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Levomilnacipran. Pentazocine may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Butethal is combined with Escitalopram. The serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Butamben is combined with Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Flupentixol. Hydroxyzine may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when clomethiazole is combined with Escitalopram. The risk or severity of adverse effects can be increased when Lormetazepam is combined with Escitalopram. Buprenorphine may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Escitalopram. Codeine may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine. The risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram. Perflutren may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram. Fingolimod may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when Ecgonine is combined with Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Bromperidol. The risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram. The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Escitalopram. The serum concentration of Escitalopram can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram. The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Escitalopram. Leuprolide may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when Chlormezanone is combined with Escitalopram. The risk or severity of adverse effects can be increased when Citalopram is combined with Escitalopram. The risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram. The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram. Remifentanil may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Methaqualone is combined with Escitalopram. Escitalopram may increase the anticoagulant activities of Phenindione. Ketobemidone may increase the serotonergic activities of Escitalopram. The metabolism of Escitalopram can be decreased when combined with Artemether. The metabolism of Escitalopram can be decreased when combined with Esomeprazole. The risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram. The risk or severity of adverse effects can be increased when Moricizine is combined with Escitalopram. The risk or severity of adverse effects can be increased when Alimemazine is combined with Escitalopram. Octreotide may increase the QTc-prolonging activities of Escitalopram. The therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram. The metabolism of Escitalopram can be decreased when combined with Ropinirole. Escitalopram may increase the anticoagulant activities of Ethyl biscoumacetate. The risk or severity of adverse effects can be increased when Tasimelteon is combined with Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Milnacipran. The risk or severity of adverse effects can be increased when Etifoxine is combined with Escitalopram. The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Escitalopram. The serum concentration of Metoprolol can be increased when it is combined with Escitalopram. The risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram. The risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram. Piritramide may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Escitalopram is combined with Cariprazine. Metronidazole may increase the QTc-prolonging activities of Escitalopram. The risk or severity of adverse effects can be increased when Difenoxin is combined with Escitalopram. The risk or severity of adverse effects can be increased when Acepromazine is combined with Escitalopram. Felbamate may increase the QTc-prolonging activities of Escitalopram. Dextromoramide may increase the serotonergic activities of Escitalopram. Minaprine may increase the serotonergic activities of Escitalopram. The risk or severity of adverse effects can be increased when Thalidomide is combined with Escitalopram. Escitalopram may increase the hypoglycemic activities of Canagliflozin. Diphenhydramine may increase the QTc-prolonging activities of Escitalopram. Histrelin may increase the QTc-prolonging activities of Escitalopram. Escitalopram may increase the hypoglycemic activities of Saxagliptin. Escitalopram may increase the hyponatremic activities of Quinethazone. Pasireotide may increase the QTc-prolonging activities of Escitalopram.